扶桑薬品工業(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証PRM | 医薬品 | 4538/E00953 | Fuso Pharmaceutical Industries, Ltd. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2020/12/30 | 日証協 | 28,349株 | -3.67% | 1,944株 | -71.16% | 41,632株 | -2.8% | 11,300株 | +20.21% |
2020/12/25 | 日証協 | 29,429株 | +12.83% | 6,740株 | +98.24% | 42,832株 | +0.47% | 9,400株 | +168.57% |
2020/12/18 | 日証協 | 26,083株 | +7.19% | 3,400株 | +41.67% | 42,632株 | +1.43% | 3,500株 | -10.26% |
2020/12/11 | 日証協 | 24,333株 | -8.81% | 2,400株 | -14.29% | 42,032株 | -1.06% | 3,900株 | +1.27% |
2020/12/04 | 日証協 | 26,684株 | -17.69% | 2,800株 | +3.7% | 42,483株 | -6.7% | 3,851株 | +196.23% |
2020/11/27 | 日証協 | 32,420株 | -10.74% | 2,700株 | -72.16% | 45,532株 | -14.94% | 1,300株 | 0% |
2020/11/20 | 日証協 | 36,320株 | +11% | 9,700株 | +29.33% | 53,532株 | +2.49% | 1,300株 | -81.94% |
2020/11/13 | 日証協 | 32,720株 | -4.94% | 7,500株 | +59.78% | 52,232株 | -3.69% | 7,200株 | -10% |
2020/11/06 | 日証協 | 34,420株 | +4.56% | 4,694株 | -50.06% | 54,232株 | +3.63% | 8,000株 | +60% |
2020/10/30 | 日証協 | 32,920株 | +13.13% | 9,400株 | +202.35% | 52,333株 | +4.81% | 5,000株 | +47.02% |
2020/10/23 | 日証協 | 29,100株 | -6.16% | 3,109株 | +29.54% | 49,933株 | +0.61% | 3,401株 | +70.05% |
2020/10/16 | 日証協 | 31,011株 | +3.47% | 2,400株 | -87.27% | 49,632株 | -1.31% | 2,000株 | -88.63% |
2020/10/09 | 日証協 | 29,971株 | +75.16% | 18,860株 | +71.14% | 50,292株 | +14.29% | 17,589株 | -13.54% |
2020/10/02 | 日証協 | 17,111株 | +41.08% | 11,020株 | +400.91% | 44,003株 | +18.5% | 20,343株 | +57.7% |
2020/09/25 | 日証協 | 12,129株 | -56.68% | 2,200株 | -65.24% | 37,132株 | -29.32% | 12,900株 | +437.5% |
2020/09/18 | 日証協 | 28,000株 | -9.15% | 6,329株 | -11.11% | 52,532株 | -2.05% | 2,400株 | -62.5% |
2020/09/11 | 日証協 | 30,820株 | -15.14% | 7,120株 | +7.88% | 53,632株 | -3.07% | 6,400株 | -24.35% |
2020/09/04 | 日証協 | 36,320株 | +2.43% | 6,600株 | +312.5% | 55,332株 | -0.97% | 8,460株 | +1310% |
2020/08/28 | 日証協 | 35,460株 | +2.01% | 1,600株 | -75% | 55,872株 | +2.76% | 600株 | -85.71% |
※株式分割は考慮していませんのでご注意ください。